Skip to main content
. 2018 Aug 24;9(66):32580–32592. doi: 10.18632/oncotarget.25953

Figure 1. Loss of E2f1 or E2f3 increases survival in osteosarcomas bearing Rb1 mutations.

Figure 1

(AD) Kaplan–Meier curves showing the survival of osteosarcoma-prone mouse models. (A) Mice bearing Rb1 mutations p53/Rb1 DKO: Osx-cre; p53lox/lox; Rb1lox/lox (black, n = 29) have significantly shorter lifespan compared to p53 cKO: Osx-cre; Tp53lox/lox (red, n = 35). This survival time was significantly increased in (B) p53/Rb1/E2f1 TKO: Osx-cre; p53lox/lox; Rb1lox/lox; E2f1−/−(red, n = 25) and (C) p53/Rb1/E2f3 TKO: Osx-cre; p53lox/lox;Rb1lox/lox; E2f3lox/lox (red, n = 34); but not in (D) p53/Rb1/E2f5 TKO: Osx-cre; p53lox/lox;Rb1lox/lox;E2f5lox/lox (red, n = 22). Mantel-Cox test and Mantel-Haenszel hazard ratio (HR) were used for curve comparisons.